Anastomosis Devices Market Size and Share
Anastomosis Devices Market Analysis by Mordor Intelligence
The anastomosis devices market generated USD 4.11 billion in 2025 and is forecast to reach USD 5.34 billion by 2030, advancing at a 5.41% CAGR. Consistent demand for dependable tissue‐connection solutions in cardiovascular, gastrointestinal and bariatric surgeries anchors this expansion. Growth momentum flows from rapid adoption of robotic-assisted connectors, rising use of bioabsorbable and hydrogel materials, and steady procedure volumes in aging populations. Manufacturers are funnelling R&D budgets toward AI-enabled stapling platforms and suture-less magnetic devices, which promise quicker healing and fewer leaks. Simultaneously, care is shifting to outpatient settings, prompting ambulatory surgical centers (ASCs) to specify lightweight, single-use systems that trim turnaround time. Yet recalls and price pressure under value-based care are tempering overall revenue acceleration.
Key Report Takeaways
- By product type, surgical staplers led with 41.24% of the anastomosis devices market share in 2024, while compression and magnetic rings & clips are projected to expand at a 7.69% CAGR through 2030.
- By usage, disposables accounted for 68.46% of the anastomosis devices market size in 2024; reusable platforms are poised for a 7.37% CAGR to 2030.
- By device technology, manual systems held 48.23% revenue share in 2024, whereas robotic-assisted and automated connectors are set for a 9.03% CAGR through 2030.
- By application, gastrointestinal surgery contributed 36.46% of 2024 revenue; bariatric and metabolic procedures show the fastest trajectory at a 9.23% CAGR to 2030.
- By end user, hospitals captured 69.36% of global sales in 2024, while ASCs are forecast to grow at 8.45% CAGR through 2030.
- By region, North America commanded 38.45% of 2024 revenue; Asia-Pacific is the fastest-growing geography at an 8.68% CAGR to 2030.
Global Anastomosis Devices Market Trends and Insights
Drivers Impact Analysis
Driver | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
---|---|---|---|
Rising volume of surgeries and mounting chronic disease burden | +1.2% | Global, strongest in North America, Europe, Japan | Long term (≥ 4 years) |
Growing adoption of minimally-invasive stapling and sealant technologies | +0.9% | North America and EU lead, APAC rapidly catching up | Medium term (2-4 years) |
Technological advancement in surgical stapling and suturing devices | +0.8% | Global, R&D centres in US, Germany, China | Medium term (2-4 years) |
Emergence of suture-less magnetic & nitinol compression devices | +0.6% | APAC core, spill-over to MEA and Latin America | Long term (≥ 4 years) |
Robotic assistance enabling automated vessel anastomosis | +0.7% | North America & EU, expanding to APAC premium markets | Medium term (2-4 years) |
Value-based care focus on post-surgical complications | +0.5% | North America leading, EU following | Short term (≤ 2 years) |
Source: Mordor Intelligence
Rising volume of surgeries and mounting chronic disease burden
Surgical procedures keep climbing as populations age and obesity, diabetes and cardiovascular disease spread across both developed and emerging regions. CMS proposed USD 7.4 billion in 2025 ASC payments—USD 202 million more than 2024—while adding 20 extra procedures to the ASC list, signaling higher case throughput.[1]Centers for Medicare & Medicaid Services, “CMS Releases 2025 Proposed Medicare Payment Rule,” ascfocus.orgSingle-anastomosis bariatric techniques such as SADI-S have delivered complete diabetes remission in Chinese cohorts, underlining procedure efficacy and demand. Each incremental case translates into multiple tissue connections, thereby raising unit consumption of anastomosis devices market products. In parallel, robotic platforms are broadening eligibility for complex gastrointestinal reconstructions, indirectly lifting device volumes. Hospitals and ASCs alike are therefore replenishing inventories of circular staplers, linear cutters and magnetic rings to keep pace with caseload growth.
Growing adoption of minimally-invasive stapling and sealant technologies
Laparoscopic and robotic workflows reduce trauma and shorten recovery, so surgeons increasingly favor powered staplers, smart sealants and articulating reloads. ETHICON’s ECHELON Powered Stapler cut bleeding complications by 73% and leaks by 85% versus manual peers. Intuitive’s SureForm features 120° articulation plus SmartFire tissue sensing, ensuring even clamp pressure and staple formation.[2]Intuitive Surgical, “SureForm Stapler with SmartFire,” intuitive.com These performance gains justify premium pricing, helping the anastomosis devices market sustain mid-single-digit growth. Investor confidence is evident, as Lexington Medical attracted growth capital to widen distribution of its minimally-invasive staplers across 35 nations. Convergence between robotics and intelligent fastening elevates technical barriers for late entrants but boosts clinical outcomes.
Technological advancement in surgical stapling and suturing devices
Innovation now targets transformative leaps in leak mitigation and workflow efficiency rather than incremental tweaks. Medtronic’s EEA Circular Stapler with Tri-Staple technology delivered 80% fewer leaks and 140% higher perfusion than rival systems. AI-driven software such as ColonPRO improved polyp-detection accuracy by 9% during colonoscopy, hinting at similar gains in intraoperative anastomosis quality. Investigators have also 3D-printed biodegradable vascular staplers that tailor fit to patient anatomy, foreshadowing custom implants. Sensor-enabled clamps already provide real-time compression metrics, helping surgeons fine-tune firing decisions. Collectively these upgrades cement longer-term demand for premium systems within the anastomosis devices market.
Emergence of suture-less magnetic & nitinol compression devices
Magnetic compression and nitinol rings realign tissue edges without leaving permanent metallic staples. GI Windows Medical secured FDA breakthrough status for a self-forming magnetic device designed for small-bowel anastomosis, accelerating its path to commercial launch.[3]GI Windows Medical, “US FDA Grants Breakthrough Designation for Self-Forming Magnetic Compression Device,” gsmedtech.com The MagDI System later received Class II clearance for duodeno-ileal bypass creation, validating regulatory acceptance of magnetics. Nitinol’s shape memory enables self-expanding couplers that apply uniform pressure as tissue swells, encouraging leak-free healing. Emerging bioabsorbable magnets further minimize foreign‐body risk once healing completes. Surgeons now view these suture-less systems as attractive solutions for delicate pediatric, bariatric and transplant cases, bolstering specialty demand in the anastomosis devices market.
Restraints Impact Analysis
Restraint | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
---|---|---|---|
Shift to catheter-based alternatives reducing CABG volumes | -0.8% | North America & EU | Medium term (2-4 years) |
High capital and single-use costs of advanced staplers/connectors | -0.6% | Global; acute in cost-sensitive markets | Short term (≤ 2 years) |
Device malfunctions and recalls affecting surgeon confidence | -0.4% | Global; regulatory attention in US/EU | Short term (≤ 2 years) |
Limited clinical evidence slowing approvals of bioabsorbable glues | -0.3% | Global, varied regulatory thresholds | Long term (≥ 4 years) |
Source: Mordor Intelligence
Shift to catheter-based alternatives reducing CABG volumes
Percutaneous coronary interventions and TAVR now treat coronary and valvular disease once reserved for open bypass, cutting surgical case volumes. Boston Scientific’s cardiovascular revenue surged 26.2% in Q1 2025 on interventional cardiology demand. Medtronic’s Evolut FX+ received FDA approval with easier coronary access, further diverting patients from surgical grafting. Cardiovascular surgeons in mature markets therefore require fewer vascular staplers and couplers, dampening one high-value segment of the anastomosis devices market. Emerging economies still rely on CABG due to limited cath-lab infrastructure, partially offsetting the decline.
High capital and single-use costs of advanced staplers/connectors
Operating budgets remain tight as reimbursement gains lag inflation. A study showed robotic stapling can cost EUR 1,500–2,000 per case versus EUR 54 for manual suturing. CMS’s 2.6% ASC rate update for 2025 provides only modest relief. Hospitals are trialling real-time cost dashboards that trimmed thoracoscopic disposable spend by 22.7%. High up-front and per-case costs slow uptake of next-gen connectors, especially in middle-income nations, tempering revenue escalation in the anastomosis devices market.
Segment Analysis
By Usage: Disposables remain dominant while reusables gain ground
Disposables secured 68.46% of the anastomosis devices market share in 2024, driven by zero-reprocessing convenience and strict infection-control protocols. Hospitals appreciate the predictable turnaround and simplified logistics, especially when high case volume stresses central-sterile departments. Many institutions embed single-use staplers into procedure packs, streamlining setup and inventory tracking. However, heightened environmental scrutiny and budget oversight are nudging procurement teams toward reusable loaders and reinforced reload cartridges. The reusable cohort is growing at 7.37% CAGR, reflecting maturation of low-temperature sterilization and validated cleaning workflows. High-volume ASCs now calculate lower total cost of ownership when cases surpass specific break-even counts, improving the segment’s prospects.
Surgeons initially voiced reliability concerns about reusable jaws and knife edges, yet iterative engineering now delivers cycle counts exceeding 50 sterilizations without staple line compromise. Capital-purchase models with vendor-managed inventory further soften adoption hurdles. While disposables will continue dominating the anastomosis devices market for the forecast period, dual-track strategies that pair single-use reloads with reusable handles are becoming common, especially in Europe’s eco-conscious facilities.
Note: Segment shares of all individual segments available upon report purchase
By Product Type: Staplers lead, compression devices accelerate
Staplers generated 41.24% of 2024 revenue and remain the default choice thanks to decades of outcome data and surgeon familiarity. Modern linear and circular variants boast triple-row staples, variable height closed-anvil designs, and refined knife blades that minimize tissue drag. Competitive benchmarking shows ETHICON PROXIMATE linear cutters achieve 34% higher leak-pressure thresholds versus alternate brands. Continuous enhancements ensure sustained demand across colorectal, bariatric and thoracic disciplines, anchoring value for incumbent suppliers.
Compression and magnetic rings & clips, although currently smaller in dollars, outpace other categories at 7.69% CAGR through 2030. FDA breakthrough designations signal clinical promise, and early studies reveal lower inflammatory profiles and elimination of retained hard-metal artifacts. Sutureless compression resonates with pediatric and transplant surgeons who prioritize growth accommodation and minimal implant burden. Success stories in animal models and initial human trials are setting the stage for broader reimbursement approval, fueling fresh momentum in the anastomosis devices market.
By Device Technology: Manual persists, robotics surges
Manual systems preserved 48.23% revenue share in 2024 since direct tactile feedback remains invaluable for tailoring bite depth and tension across heterogeneous tissue. Surgeons also appreciate the ability to troubleshoot bleeding immediately after the fire, a nuance still challenging for automation. Powered staplers bridge convenience and surgeon control by lowering squeeze force, particularly beneficial in lengthy bariatric sleeves.
Robotic-assisted connectors are the fastest-rising slice at 9.03% CAGR, thanks to precision articulation and data-rich interfaces. The da Vinci SureForm supplies 120° articulation, enabling deep pelvic anastomosis without rescoping. Automated connectors are now entering trials, aiming to standardize distance between bites and ensure perfect lumen alignment. While capital intensive, these innovations attract flagship academic centers that anchor early adoption curves in the anastomosis devices market.
By Material: Metallic reliability challenged by bioabsorbables
Metallic frames—chiefly stainless steel, titanium and nitinol—underpinned 54.36% of sales in 2024 owing to their strength and corrosion resistance. Nitinol’s shape memory lets couplers expand gently, aligning edges without surgeon micromanagement. Still, the permanence of metal invites long-term artifact concerns in imaging and growth-related complications in pediatrics. Consequently, bioabsorbable polymers and hydrogel composites are climbing at 8.89% CAGR by delivering temporary support that dissolves once healing finalizes. Marine-inspired hydrogel barriers demonstrated improved vascularisation and reduced adhesions in animal anastomoses. Advances in processing are lifting mechanical thresholds, helping bioabsorbables encroach on metallic hegemony in the anastomosis devices market.
Polymer alternatives such as PEEK and polypro ¬pylene serve niches where radiolucency eases post-operative imaging. Drug-eluting layers that release anti-inflammatory agents or growth factors deepen differentiation. As suppliers lock in scalable extrusion and 3D-printing lines, unit cost gaps with metal narrow, making bioabsorbables commercially attractive.
By Application: Gastrointestinal dominance, bariatric momentum
Gastrointestinal (GI) surgery claimed 36.46% of 2024 revenue, benefitting from large procedure volumes in colorectal cancer, Crohn’s disease and ulcerative colitis. Multi-quadrant resections often need two or more anastomoses, multiplying device count per case. Enhanced recovery protocols prioritise leak-free staple lines to avoid costly readmissions, ensuring steady demand for premium reloads within the anastomosis devices market size for this segment.
Bariatric and metabolic operations are expanding fastest at 9.23% CAGR, propelled by global obesity prevalence. Sleeve gastrectomy and SADI-S procedures each rely on long staple lines plus one critical duodeno-ileal connection. Early Chinese experience reported zero leak-related mortality, bolstering surgeon confidence. Emerging economies with rising BMI profiles now reimburse bariatric surgery, widening addressable volume. Cardiovascular, organ transplant and dialysis access remain important but slower-growing domains, often requiring specialty connectors with premium ASPs.

Note: Segment shares of all individual segments available upon report purchase
By End User: Hospitals remain anchor, ASCs eclipse growth
Hospitals absorbed 69.36% of worldwide revenue in 2024, reflecting their role in high-acuity reconstructions, trauma and transplant cases that demand broad device catalogues on hand. Centralised purchasing negotiates volume discounts and fosters vendor standardisation. Training fellowships also expose residents to branded systems, reinforcing institutional loyalty in the anastomosis devices market.
ASCs, however, are sprinting ahead at 8.45% CAGR as payers squeeze inpatient reimbursements. CMS’s 2025 proposal lifts ASC payments to USD 7.4 billion and adds 20 procedures to the covered list. Surgeons cherish faster turnover and patient satisfaction, while operators value lower facility overhead. Device makers now craft compact, sterile-packed kits tailored to ASC floorplans, courting this growth pocket. Specialty clinics devoted to bariatric or colorectal care further diversify channels, adopting advanced materials to differentiate outcomes.
Geography Analysis
North America controlled 38.45% of global revenue in 2024, underpinned by concentrated R&D clusters, early technology adoption and robust reimbursement pathways. FDA breakthrough and 510(k) programs accelerate time-to-market for novel compression devices, while large integrated health networks enable swift rollouts across multiple states. Nonetheless, value-based purchasing exerts downward pressure on price, compelling suppliers to emphasise evidence of reduced readmission and leak rates to sustain margin.
Europe follows with strong yet varied demand shaped by national procurement rules and the Medical Device Regulation’s heightened evidence bar. Germany and France champion robotic stapling adoption due to high hospital capital budgets, whereas Southern European systems prioritise cost-effectiveness. Post-Brexit regulatory divergence necessitates separate UK certifications, elongating launch timelines and modestly restraining short-term growth in the anastomosis devices market.
Asia-Pacific registers the fastest CAGR at 8.68% through 2030, thanks to rising disposable incomes, infrastructure expansion and government healthcare investments. Retrospective analysis of 827 robotic SADI-S patients in a Chinese center showed complication rates comparable to gastric bypass, validating local skill levels. Japan’s super-aged demographic demands leak-proof vascular and GI anastomoses, while South Korea’s medical-tourism clusters adopt cutting-edge staplers to attract overseas patients. India implemented a marketing conduct code in 2024, signalling maturing regulatory oversight that encourages multinational entrants. Diverse income tiers generate parallel demand for premium robotic reloads and economical manual staplers, broadening the anastomosis devices market footprint.

Competitive Landscape
The anastomosis devices market is moderately consolidated. Medtronic, Johnson & Johnson and Boston Scientific leverage extensive patent estates, global service teams and recurring reload revenue to secure hospital contracts. Boston Scientific’s USD 1.26 billion Silk Road Medical acquisition reinforced its position in neurovascular access, combining stroke-prevention devices with anastomotic expertise. Merit Medical’s USD 120 million Biolife purchase broadened its haemostatic range, enhancing complementary offerings for post-anastomosis care.
Technology differentiation shapes new entrants’ prospects. Phraxis gained FDA clearance in May 2025 for its Endoforce Connector, a minimally invasive fistula coupler for dialysis access, demonstrating how niche innovation can pierce incumbent walls. GI Windows and Ossio are racing to secure human data for magnetic and bio-integrative staples respectively, positioning themselves as disruptors. Meanwhile, large strategics pursue ecosystem plays: Karl Storz agreed to acquire Asensus Surgical, bringing in digital laparoscopy insights that mesh with stapling portfolios.
Regional manufacturers are also rising. Chinese OEMs supported by domestic procurement quotas offer cost-competitive manual staplers, capturing mid-tier hospitals. Indian firms emphasise reusable platforms aligned with sustainability mandates. Competitive intensity thus spans premium tech battles and price-driven skirmishes, ensuring innovation pipelines remain robust over the forecast horizon.
Anastomosis Devices Industry Leaders
-
Medtronic plc
-
Johnson & Johnson
-
Baxter
-
B. Braun SE
-
Boston Scientific Corp
- *Disclaimer: Major Players sorted in no particular order

Recent Industry Developments
- June 2025: Johnson & Johnson MedTech introduced a surgical stapler built for complex tissue layers, aiming to cut leaks in challenging GI sites.
- May 2025: Phraxis Inc. received FDA approval for its Endoforce Connector for venous dialysis anastomosis, avoiding surgical dissection and reducing trauma.
- May 2025: Merit Medical finalised a USD 120 million purchase of Biolife, adding StatSeal and WoundSeal haemostatic products to its stable.
- May 2025: Lexington Medical secured growth funding from Ampersand Capital Partners to accelerate its minimally invasive stapling portfolio across 35 countries.
Global Anastomosis Devices Market Report Scope
As per the report's scope, anastomosis is a surgical procedure that involves connecting two structures and is performed after the resection of an organ to connect the remaining sections. It is a critical step in surgery and has a high risk for complications, which requires highly efficient and advanced devices to perform. The anastomosis devices market is segmented by usage (disposable and reusable), type (surgical staplers, surgical sutures, surgical sealants and adhesives, and other types), application (cardiovascular surgery, gastrointestinal surgery, and others), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers the value (USD) for the above segments.
By Usage | Disposable | ||
Reusable | |||
By Product Type | Surgical Staplers | ||
Surgical Sutures | |||
Surgical Sealants & Adhesives | |||
Compression / Magnetic Rings & Clips | |||
By Device Technology | Manual | ||
Powered | |||
Robotic-assisted / Automated Connectors | |||
By Material | Metallic (Stainless Steel, Titanium, Nitinol) | ||
Polymer (PP, ABS, PEEK) | |||
Bio-absorbable / Hydrogel | |||
By Application | Cardiovascular Surgery | ||
Gastrointestinal Surgery | |||
Bariatric & Metabolic Surgery | |||
Organ Transplant & Dialysis Access | |||
Others (Thoracic, Neuro, Urology) | |||
By End User | Hospitals | ||
Ambulatory Surgical Centers | |||
Specialty Clinics | |||
By Geography | North America | United States | |
Canada | |||
Mexico | |||
Europe | Germany | ||
United Kingdom | |||
France | |||
Italy | |||
Spain | |||
Rest of Europe | |||
Asia-Pacific | China | ||
Japan | |||
India | |||
Australia | |||
South Korea | |||
Rest of Asia-Pacific | |||
Middle East and Africa | GCC | ||
South Africa | |||
Rest of Middle East and Africa | |||
South America | Brazil | ||
Argentina | |||
Rest of South America |
Disposable |
Reusable |
Surgical Staplers |
Surgical Sutures |
Surgical Sealants & Adhesives |
Compression / Magnetic Rings & Clips |
Manual |
Powered |
Robotic-assisted / Automated Connectors |
Metallic (Stainless Steel, Titanium, Nitinol) |
Polymer (PP, ABS, PEEK) |
Bio-absorbable / Hydrogel |
Cardiovascular Surgery |
Gastrointestinal Surgery |
Bariatric & Metabolic Surgery |
Organ Transplant & Dialysis Access |
Others (Thoracic, Neuro, Urology) |
Hospitals |
Ambulatory Surgical Centers |
Specialty Clinics |
North America | United States |
Canada | |
Mexico | |
Europe | Germany |
United Kingdom | |
France | |
Italy | |
Spain | |
Rest of Europe | |
Asia-Pacific | China |
Japan | |
India | |
Australia | |
South Korea | |
Rest of Asia-Pacific | |
Middle East and Africa | GCC |
South Africa | |
Rest of Middle East and Africa | |
South America | Brazil |
Argentina | |
Rest of South America |
Key Questions Answered in the Report
1. What is the expected value of the anastomosis devices market by 2030?
The anastomosis devices market is projected to reach USD 5.34 billion by 2030 at a 5.41% CAGR.
2. Which product segment currently leads revenue?
Surgical staplers lead with 41.24% of global revenue in 2024 due to extensive clinical validation and surgeon familiarity.
3. Why are ambulatory surgical centers important to future growth?
ASCs are expanding case volumes rapidly and are forecast to grow device purchases at 8.45% CAGR as more procedures shift to outpatient care.
4. Which geographic region will grow the fastest?
Asia-Pacific is the fastest-growing region, advancing at an 8.68% CAGR through 2030 on the back of infrastructure investment and rising chronic disease prevalence.
5. What technology trends are reshaping competition?
Robotic-assisted stapling, AI-enabled guidance, and suture-less magnetic compression devices are differentiating next-generation platforms and attracting investment.